252 related articles for article (PubMed ID: 8486636)
1. A variant of exotoxin A that forms potent and specific chemically conjugated immunotoxins.
Chaudry GJ; Fulton RJ; Draper RK
J Biol Chem; 1993 May; 268(13):9437-41. PubMed ID: 8486636
[TBL] [Abstract][Full Text] [Related]
2. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Brinkmann U; Reiter Y; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7538-42. PubMed ID: 8356052
[TBL] [Abstract][Full Text] [Related]
3. A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines.
Klimka A; Barth S; Drillich S; Wels W; van Snick J; Renauld JC; Tesch H; Bohlen H; Diehl V; Engert A
Cytokines Mol Ther; 1996 Sep; 2(3):139-46. PubMed ID: 9384698
[TBL] [Abstract][Full Text] [Related]
4. A dipeptide insertion in domain I of exotoxin A that impairs receptor binding.
Chaudry GJ; Wilson RB; Draper RK; Clowes RC
J Biol Chem; 1989 Sep; 264(25):15151-6. PubMed ID: 2570071
[TBL] [Abstract][Full Text] [Related]
5. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
6. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv).
Batra JK; Fitzgerald DJ; Chaudhary VK; Pastan I
Mol Cell Biol; 1991 Apr; 11(4):2200-5. PubMed ID: 2005905
[TBL] [Abstract][Full Text] [Related]
7. Exotoxin A of Pseudomonas aeruginosa: substitution of glutamic acid 553 with aspartic acid drastically reduces toxicity and enzymatic activity.
Douglas CM; Collier RJ
J Bacteriol; 1987 Nov; 169(11):4967-71. PubMed ID: 2889718
[TBL] [Abstract][Full Text] [Related]
8. Exotoxin A of Pseudomonas aeruginosa: evidence that domain I functions in receptor binding.
Guidi-Rontani C; Collier RJ
Mol Microbiol; 1987 Jul; 1(1):67-72. PubMed ID: 2838729
[TBL] [Abstract][Full Text] [Related]
9. Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.
Benhar I; Padlan EA; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12051-5. PubMed ID: 7991583
[TBL] [Abstract][Full Text] [Related]
10. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
[TBL] [Abstract][Full Text] [Related]
11. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
Barth S; Huhn M; Wels W; Diehl V; Engert A
Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
[TBL] [Abstract][Full Text] [Related]
12. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol.
Ogata M; Fryling CM; Pastan I; FitzGerald DJ
J Biol Chem; 1992 Dec; 267(35):25396-401. PubMed ID: 1460035
[TBL] [Abstract][Full Text] [Related]
13. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Barth S; Matthey B; Huhn M; Diehl V; Engert A
Cytokines Cell Mol Ther; 1999 Jun; 5(2):69-78. PubMed ID: 10515679
[TBL] [Abstract][Full Text] [Related]
14. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
Batra JK; Kasprzyk PG; Bird RE; Pastan I; King CR
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5867-71. PubMed ID: 1352878
[TBL] [Abstract][Full Text] [Related]
15. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.
Brinkmann U; Lee BK; Pastan I
J Immunol; 1993 Apr; 150(7):2774-82. PubMed ID: 8454854
[TBL] [Abstract][Full Text] [Related]
16. Expression cloning of cDNAs that render cancer cells resistant to Pseudomonas and diphtheria toxin and immunotoxins.
Brinkmann U; Brinkmann E; Pastan I
Mol Med; 1995 Jan; 1(2):206-16. PubMed ID: 8529099
[TBL] [Abstract][Full Text] [Related]
17. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
Kuan CT; Pastan I
Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123
[TBL] [Abstract][Full Text] [Related]
18. An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin.
Debinski W; Pastan I
Bioconjug Chem; 1994; 5(1):40-6. PubMed ID: 8199233
[TBL] [Abstract][Full Text] [Related]
19. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I
Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas exotoxin A-epidermal growth factor (EGF) mutant chimeric protein as an indicator for identifying amino acid residues important in EGF-receptor interaction.
Shiah HS; Chen TY; Chang CM; Chow JT; Kung HJ; Hwang J
J Biol Chem; 1992 Nov; 267(33):24034-40. PubMed ID: 1429738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
